Seminars in Thrombosis and Hemostasis: 2024 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

This Editorial continues the now standard approach to announce the newest Seminars in Thrombosis and Hemostasis (STH) Journal Impact Factor (IF) and other journal metrics, upon release of the latest IF.[1] [2] [3] [4]

2024 STH Impact Factor

The latest IF for STH, as for all journals with an IF, was announced in mid-June of 2025, which was for the year 2024. The 2024 IF for STH was 4.1, which marked an increase over the 2023 IF, which was 3.6. For the interest of the readership, I have provided a figure outlining the STH IF from 2003 to 2024 ([Fig. 1]). The 2021 IF of 6.398 was the highest IF that STH has ever achieved. Some of these IF variations were anticipated.

Fig. 1 The impact factor for Seminars in Thrombosis and Hemostasis from 2003 to 2024.

First, there have been some notable changes to how the IF is calculated in recent years. Whereas IF data historically reflected dates of final (e.g., print) publication, a change was instigated for 2020 to include dates of online publication, which for most journals occurs several months ahead of final print versions. These are called eFirst articles for STH, and are available @ <https://www.thieme-connect.com/products/ejournals/issue/eFirst/10.1055/s-00000077>. Since moving to online submissions via ScholarOne, STH is also publishing some materials ahead of eProofing and eFirst, called early online “Accepted Manuscripts,” and hosted @ <https://www.thieme-connect.com/products/ejournals/issue/aam/10.1055/s-00000077>. These are only posted for manuscripts where authors have chosen this option. In any case, both versions of these online manuscripts are published well ahead of the final compiled issues (hosted @ <https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>). The change in IF calculation progressed further in 2021 to utilize dates of online publication instead of final print. Further adjustment to the IF calculation occurred for the 2022 year.

Second, the list of journals included in the database used for generating IFs are subject to change, with additional citation potential from the inclusion of additionally added journals. Third, we were all affected by the COVID-19 (coronavirus disease 2019) pandemic. One silver lining to the pandemic was the incredible drive by scientific and medical teams to understand and combat the virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the infectious agent leading to COVID-19. The majority of countries have stopped reporting statistics, but according to available data, COVID-19 has infected nearly 800 million people worldwide, and is responsible for over 7 million deaths.[5]

One amazing medical/scientific achievement in response to COVID-19 was the rapid development, production, and deployment of a multitude of COVID-19/SARS-CoV-2 vaccines, nearly 14 billion doses of which have since been administered.[6] The pandemic also created research and writing “frenzies,” with 480,700 COVID-19-related publications now listed in PubMed,[7] with just 121 of these publications attributable to STH. It should be highlighted that although COVID-19 constitutes an infectious disease, it also constitutes a prothrombotic disease, and thus many COVID-19-related papers have appeared in thrombosis and hemostasis (T&H)-related journals. Indeed, STH previously published four specifically themed issues entirely focused on COVID-19,[8] [9] [10] [11] one in each year during 2020–2023. Moreover, much of the COVID-19-related material was made freely available by the publisher. It has since become clear that these publications were both quite popular with the readership,[12] [13] [14] [15] and also well-cited in the literature.[1] [2] [3] [4]

Thus, to some extent, an increase in the IF for 2021 was predicted for most T&H focused journals, including STH, and was in part driven by COVID-19-related publications ([Fig. 2]).[2] However, as the COVID-19 pandemic turned into an endemic that we now continue to live with, and as we all go back to “business as usual,” it could also be anticipated that the 2022 and 2023 IFs would correspondingly fall for all T&H focused journals, including STH ([Fig. 2]). I have included several figures here that compare the IF changes across several T&H focused journals. [Fig. 2] shows the changes in IF for several T&H focused journals from year to year from 2001. The STH IF has always been somewhere in the middle of the group. Interestingly, the IF for the majority of these journals for 2024 was between 2 and 5. [Fig. 3] shows the changes in IF for several T&H focused journals from year to year for the past 5 years; the change from 2019 to 2020 is shown in [Fig. 3A], that from 2020 to 2021 shown in [Fig. 3B], that from 2021 to 2022 shown in [Fig. 3C], that from 2022 to 2023 shown in [Fig. 3D], and the final change from 2023 to 2024 shown in [Fig. 3E]. In general, most T&H focused journals showed an increase in IF in both 2019 to 2020 and 2020 to 2021, representing the periods of greatest interest in COVID-19, but then showed subsequent reductions in IF from 2021 to 2022, and from 2022 to 2023, and also from 2023 to 2024. Indeed, some journals achieved a huge increment in IF in 2021 on the back of a few very highly cited COVID-19 publications (some of these received in excess of 2,000 citations). However, these journals in general also showed the largest proportional falls in 2022 and 2023 IFs. Of course, we also need to factor in the changes in the IF calculations over recent years, moving from print to online publications, and changes to the included journals in the citation database. In any case, it is likely that IFs will now begin to stabilize and perhaps 2024 represents a transition to some sort of new equilibrium.

Fig. 2 The evolution in impact factor for Seminars in Thrombosis and Hemostasis and several other journals focused on thrombosis and hemostasis between 2001 and 2024.

Fig. 3 The change in impact factor (IF) for Seminars in Thrombosis and Hemostasis (STH) and several other journals focused on thrombosis and hemostasis (T&H) between 2020 and 2019 (A), 2021 and 2020 (B), 2022 and 2021 (C), 2023 and 2022 (D), and most recently between 2024 and 2023 (E). Trends in T&H focused journals were broadly similar, with generalized increases in 2020 and 2021, and then generalized falls in 2022, 2023, and 2024. STH was unique among these journals by showing an increase in IF in 2024.

It is of course also important to note that the IFs for STH in 2021 and 2022 were not solely related to an increase in citations of COVID-19 material.[2] [3] Finally, the IF is just only one of several markers of journal “quality” that we should consider, and the limitations of any individual marker (including the IF) as a “quality” indicator have previously been discussed.[16] [17]

Thus, perhaps a better indicator of ongoing “quality” is specific related ranking among peer journals. STH was ranked 21/98 in the Hematology category of the Science Citation Index Expanded (SCIE) in 2024, compared with 25/97 in 2023, 20/79 in 2022, 21/78 in 2021, 28/76 in 2020, and 36/76 in 2019. Similarly, STH was ranked 20/98 in the Peripheral Vascular Disease category of the SCIE in 2024, compared with 22/96 in 2023, 15/67 in 2022, 14/67 in 2021, 21/65 in 2020, and 26/65 in 2019. Importantly, STH remains in Quartile 1 of the Peripheral Vascular Disease category, and has also moved into the Quartile 1 category for Hematology.

 

MissingLinkText

Most Highly Cited Papers Contributing to the 2024 STH Impact Factor

As I also now do annually,[1] [2] [3] [4] the highest 2024-cited (2022/2023-published) contributions[18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] from this journal are listed in [Table 1] for the potential interest of the readership and contributing authors. [Table 1] identifies STH publications that most contributed to the 2024 IF, and each publication was cited 6 or more times in the IF database literature in 2024. It should be noted that “published” for the newest IF calculations means initial (online) publication date, whereas in the past, the final publication date would have been used. As an example of the effect of this change on citations, I also provide [Table 2], which identifies five additional papers with high citation rates in 2024, and with final publication date in 2022,[50] [51] [52] [53] [54] but which were not included in the 2024 IF calculations since their first online publication date was 2021. Indeed, no paper was included in [Table 1] from the first or second published issue of 2022 (February and March), since all of these papers had already been published online in 2021, and thus no longer qualified for the 2024 IF. This marks a big shift in the IF listings, since in the past, the first (February) and second (March) issues published in STH enjoyed a historical advantage for the IF calculation in a subsequent cycle, given their longest exposure for potentially accumulating citations. As the IF calculation now comprises online publication dates, the potential contribution of final published issues has become more balanced.

Table 1 Top 2024-cited papers, as published in 2022/2023[a]

Citation rank	Citation/Reference	Manuscript type
1	Morrow GB, Mutch NJ. Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1). Semin Thromb Hemost. 2023 Apr;49(3):305–313.	Review
2	Franchini M, Mannucci PM. The More Recent History of Hemophilia Treatment. Semin Thromb Hemost. 2022 Nov;48(8):904–910.	Review
3	Iba T, Wada H, Levy JH. Platelet Activation and Thrombosis in COVID-19. Semin Thromb Hemost. 2023 Feb;49(1):55–61.	Review
3	Hartmann J, Dias JD, Pivalizza EG, Garcia-Tsao G. Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled Trials. Semin Thromb Hemost. 2023 Mar;49(2):162–172.	Review
4	Iba T, Levi M, Thachil J, Levy JH. Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations. Semin Thromb Hemost. 2022 Nov;48(8):978–987.	Review
4	Moore GW. Testing for Lupus Anticoagulants. Semin Thromb Hemost. 2022 Sep;48(6):643–660.	Review
5	Okholm SH, Krog J, Hvas AM. Tranexamic Acid and Its Potential Anti-inflammatory Effect: A Systematic Review. Semin Thromb Hemost. 2022 Jul;48(5):568–595.	Review
5	Bowyer AE, Gosselin RC. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments. Semin Thromb Hemost. 2023 Sep;49(6):609–620.	Review
5	Thachil J, Favaloro EJ, Lippi G. D-dimers—“Normal” Levels versus Elevated Levels Due to a Range of Conditions, Including “D-dimeritis,” Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. Semin Thromb Hemost. 2022 Sep;48(6):672–679.	Review
6	Warkentin TE, Greinacher A. Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review. Semin Thromb Hemost. 2023 Sep;49(6):621–633.	Review
6	Turner S, Naidoo CA, Usher TJ, Kruger A, Venter C, Laubscher GJ, Khan MA, Kell DB, Pretorius E. Increased Levels of Inflammatory and Endothelial Biomarkers in Blood of Long COVID Patients Point to Thrombotic Endothelialitis. Semin Thromb Hemost. 2024 Mar;50(2):288–294.	Commentary
7	Grobbelaar LM, Kruger A, Venter C, Burger EM, Laubscher GJ, Maponga TG, Kotze MJ, Kwaan HC, Miller JB, Fulkerson D, Huff W, Chang E, Wiarda G, Bunch CM, Walsh MM, Raza S, Zamlut M, Moore HB, Moore EE, Neal MD, Kell DB, Pretorius E. Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared with the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. Semin Thromb Hemost. 2022 Oct;48(7):858–868.	Original Study
7	Richard M, Celeny D, Neerman-Arbez M. Mutations Accounting for Congenital Fibrinogen Disorders: An Update. Semin Thromb Hemost. 2022 Nov;48(8):889–903.	Review
7	Bartlett R, Arachichilage DJ, Chitlur M, Hui SR, Neunert C, Doyle A, Retter A, Hunt BJ, Lim HS, Saini A, Renné T, Kostousov V, Teruya J. The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation. Semin Thromb Hemost. 2024 Feb;50(1):81–90.	Review
8	Candeloro M, Schulman S. Arterial Thrombotic Events in Hospitalized COVID-19 Patients: A Short Review and Meta-analysis. Semin Thromb Hemost. 2023 Feb;49(1):47–54.	Review
8	Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-Pulmonary Embolism Syndrome and Functional Outcomes after Acute Pulmonary Embolism. Semin Thromb Hemost. 2023 Nov;49(8):848–860.	Review
8	Hu M, Li X, Yang Y. Causal Associations Between Cardiovascular Risk Factors and Venous Thromboembolism. Semin Thromb Hemost. 2023 Oct;49(7):679–687.	Original Study
8	Adcock DM, Moore GW, Montalvão SL, Kershaw G, Gosselin RC. Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art. Semin Thromb Hemost. 2023 Sep;49(6):571–579.	Review
9	Devreese KMJ. Solid Phase Assays for Antiphospholipid Antibodies. Semin Thromb Hemost. 2022 Sep;48(6):661–671.	Review
9	Larsen JB, Hvas AM, Hojbjerg JA. Platelet Function Testing: Update and Future Directions. Semin Thromb Hemost. 2023 Sep;49(6):600–608.	Review
9	Casini A, Moerloose P, Neerman-Arbez M. One Hundred Years of Congenital Fibrinogen Disorders. Semin Thromb Hemost. 2022 Nov;48(8):880–888.	Review
9	Favaloro EJ, Dean E, Arunachalam S. Variable Performance of Lupus Anticoagulant Testing: The Australasian/Asia-Pacific Experience. Semin Thromb Hemost. 2024 Nov;50(8):1103–1113.	Original Study
10	Mabrouk M, Guessous F, Naya A, Merhi Y, Zaid Y. The Pathophysiological Role of Platelet-Derived Extracellular Vesicles. Semin Thromb Hemost. 2023 Apr;49(3):279–283.	Review
10	Ortega-Paz L, Talasaz AH, Sadeghipour P, Potpara TS, Aronow HD, Jara-Palomares L, Sholzberg M, Angiolillo DJ, Lip GYH, Bikdeli B. COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. Semin Thromb Hemost. 2023 Nov;49(8):816–832.	Review
10	Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia. Semin Thromb Hemost. 2023 Jul;49(5):444–452.	Review
10	Bikdeli B, Muriel A, Wang Y, Piazza G, Khairani CD, Rosovsky RP, Mehdipoor G, O'Donoghue ML, Madridano O, Lopez-Saez JB, Mellado M, Brasero AMD, Grandone E, Spagnolo PA, Lu Y, Bertoletti L, López-Jiménez L, Núñez MJ, Blanco-Molina Á, Gerhard-Herman M, Goldhaber SZ, Bates SM, Jimenez D, Krumholz HM, Monreal M; RIETE Investigators. Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study. Semin Thromb Hemost. 2023 Oct;49(7):725–735.	Original Study
10	Boccatonda A, Balletta M, Vicari S, Hoxha A, Simioni P, Campello E. The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review. Semin Thromb Hemost. 2023 Oct;49(7):744–755.	Review
10	Gyldenholm T, Hvas AM, Christensen TD, Larsen JB. Thrombin Generation Markers as Predictors of Cancer-Associated Venous Thromboembolism: A Systematic Review. Semin Thromb Hemost. 2024 Apr;50(3):384–401.	Review
10	Shavit-Stein E, Berkowitz S, Gofrit SG, Altman K, Weinberg N, Maggio N. Neurocoagulation from a Mechanistic Point of View in the Central Nervous System. Semin Thromb Hemost. 2022 Apr;48(3):277–287.	Review
10	Lira AL, Kohs TCL, Moellmer SA, Shatzel JJ, McCarty OJT, Puy C. Substrates, Cofactors, and Cellular Targets of Coagulation Factor XIa. Semin Thromb Hemost. 2024 Oct;50(7):962–969.	Review
10	Radin M, Cecchi I, Arbrile M, Montin D, Farinasso L, Cioffi M, Foddai SG, Barinotti A, Menegatti E, Baldovino S, Sciascia S, Roccatello D. Pediatric Presentation of Antiphospholipid Syndrome: A Review of Recent Literature with Estimation of Local Prevalence. Semin Thromb Hemost. 2024 Mar;50(2):182–187.	Review
10	George JN. Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond. Semin Thromb Hemost. 2022 Nov;48(8):926–936.	Review

^a These papers were cited 6 or more times in 2024 and were published in 2022/2023 according to the revised impact factor (IF) calculation (i.e., using online publication dates); thus, these papers contributed most to the STH 2024 IF. Citation rank is rank according to number of citations; publications with the same number of citations have been given the same rank.

Table 2 Additional top 2024-cited papers, as published with final publication date of 2022, but preceding online publication date of 2021[a]

Citation rank	Citation/Reference	Manuscript type
1	Kearney KJ, Ariëns RAS, Macrae FL. The Role of Fibrin(ogen) in Wound Healing and Infection Control. Semin Thromb Hemost. 2022 Mar;48(2):174–187.	Review
2	Schellong S, Ageno W, Casella IB, Chee KH, Schulman S, Singer DE, Desch M, Tang W, Voccia I, Zint K, Goldhaber SZ. Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. Semin Thromb Hemost. 2022 Jun;48(4):446–458.	Original Study
3	Bahraini M, Dorgalaleh A. The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19. Semin Thromb Hemost. 2022 Feb;48(1):19–30.	Review
3	Bor MV, Feddersen S, Pedersen IS, Sidelmann JJ, Kristensen SR. Dysfibrinogenemia—Potential Impact of Genotype on Thrombosis or Bleeding. Semin Thromb Hemost. 2022 Mar;48(2):161–173.	Review
3	Favaloro EJ, Henry BM, Lippi G. Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. Semin Thromb Hemost. 2022 Feb;48(1):55–71.	Review

^a These papers were cited 6 or more times in 2024 and were published in final form in 2022, but given earlier online publication in 2021, these papers did not contribute to the STH 2024 impact factor (IF) (i.e., according to the revised IF calculation using online publication dates). Citation rank is rank according to number of citations; publications with the same number of citations have been given the same rank.

For those interested, the current listings ([Tables 1] and [2])[18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] can be compared with those of the most recently published top downloaded article listings from STH, the basis of the Eberhard F. Mammen “Most Popular” awards.[12] [13] [14] [15]

Most of the manuscripts appearing in [Tables 1] and [2] represent review articles, since STH publishes mostly review articles. Nevertheless, quite a few original studies also appear in [Tables 1] and [2], as does one Commentary. Although COVID-19 is no longer a specific focus of the journal, many of the listed papers are related to COVID-19, with many of these also listed in the most popular listings,[12] [13] [14] [15] as well as in prior high citation lists.[2] [3] [4] It therefore continues to be pleasing that there is at least partial concordance between popularity (as assessed by article downloads)[12] [13] [14] [15] and a paper's “impact” (as judged by the number of citations; [Tables 1] and [2]).[1] [2] [3] [4] It is also pleasing to continue to see Young Investigator winners appearing in these lists. This vindicates the Editorial decision to publish select original studies, and also the publisher's continued support of the Young Investigator awards.

Several past issues of the journal are also worthy of highlighting as most contributing to the 2024 IF. Six issues of STH managed to achieve a total citation count of more than 30 citations per issue[11] [55] [56] [57] [58] [59]:

1. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part I.[55] Guest Editor: Emmanuel J. Favaloro. Published in November 2022, this issue generated 62 citations in 2024, and includes four papers in [Table 1].

2. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis-Part II.[56] Guest Editor: Emmanuel J. Favaloro. Published in April 2023, this issue generated 46 citations in 2024, and includes two papers in [Table 1], including the top-cited manuscript.

3. Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part II.[57] Guest Editors: Kristi Smock and Robert C. Gosselin. Published in September 2023, this issue generated 45 citations in 2024, and includes four papers in [Table 1].

4. Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part I.[58] Guest Editors: Kristi Smock and Robert C. Gosselin. Published in September 2022, this issue generated 35 citations in 2024, and includes three papers in [Table 1].

5. Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part IV.[11] Guest Editors: Emmanuel J. Favaloro, Leonardo Pasalic, and Giuseppe Lippi. Published in February 2023, this issue generated 34 citations in 2024, and includes two papers in [Table 1].

6. Recent Advances in Thrombosis and Hemostasis-Part IX.[59] Guest Editor: Sam Schulman. Published in October 2023, this issue also generated 34 citations in 2024, and includes three papers in [Table 1].

 

MissingLinkText

Metrics Around Publication Acceptance Rates

This editorial also provides an opportunity to update the readership on some metrics around submission and acceptance rates for unsolicited manuscripts. As previously noted, STH now publishes a mixture of themed and non-themed “composite” issues.[60] All issues of STH contain around 10 full articles each, for a total of about 80 full articles per year (in total 8 issues/year). The vast majority of full articles published in STH are reviews, in keeping with our past publication history and our primary focus as a review journal. However, as we move somewhat away from a purely specifically themed issue concept, STH now also publishes unsolicited material, including the occasional original study, although these are limited to a maximum of around 10 or so per year (or approximately 15% of full article content). Moreover, original studies are more likely to be published in the non-specifically themed “composite” issues, and more likely to constitute unsolicited material. In contrast, most content in the specifically themed issues would represent solicited material, and thus mostly reviews. Of course, some original papers may form a very small component of specifically themed issues, and indeed could also originate from solicited material. Irrespective, what this all means is that STH receives similar equal numbers of unsolicited reviews and original studies, but original studies are more likely to be declined.

Some data from 2015 to 2024 are shown in [Figs. 4] to [6]. [Fig. 4] shows the trends for unsolicited papers received versus published in STH over the years 2015 to 2024. As shown, STH currently receives close to 40 to 50 unsolicited original studies and unsolicited reviews per year; STH also receives several Letters to the Editor (“Correspondence”) per year. In total, STH receives close to 100 unsolicited items/year. In some years, an increase in Letters to the Editor (“Correspondence”) received was observed, in part because we advise some authors of original articles, for which we decline to publish as original articles, that STH might instead consider publishing a portion of their study if resubmitted as Correspondence.

Fig. 4 Annual trends analysis 1: Number of unsolicited manuscripts received and published in Seminars in Thrombosis and Hemostasis by year from 2015 to 2024 for reviews, full-length original study articles, and Letters to the Editor (“Correspondence”).

Fig. 5 Annual trends analysis 2: Percentage of respective unsolicited items from [Fig. 4] published in Seminars in Thrombosis and Hemostasis by year from 2015 to 2024 for reviews, full-length original study articles, and Letters to the Editor (“Correspondence”).

Fig. 6 Number of pages (left y-axis) and number of issues (right y-axis) published in Seminars in Thrombosis and Hemostasis per year, from year 1974 to 2024.

STH publishes only a proportion of the unsolicited manuscripts received (about 10 original studies per year; around 20 unsolicited reviews/year) ([Fig. 4]). Additional clarity is provided in [Fig. 5], which shows the proportion of unsolicited manuscripts published by year; only approximately 20% of unsolicited original studies and approximately 50 to 60% of unsolicited reviews are published per year. This data needs to consider the number of submissions received for additional context; for example, although we published 100% of correspondences received in the years 2015 and 2016 ([Fig. 5]), we received very few such papers in these years ([Fig. 4]). In total, STH has published from 0 to 11 original papers per year from 2015 to 2024 ([Fig. 4]), with this representing an overall average of <20% of all original papers received over these years ([Fig. 5]). STH also publishes a Preface with each issue, as well as several Editorials per year.

The final data that I will share are shown in [Figs. 6] and [7]. [Fig. 6] shows both the number of issues of STH published per year, as well as the number of pages published per year in the print issues. STH began in 1974, with the journal publishing just two issues per year, under the direction of the Founding Editor in Chief, Eberhard F. Mammen. STH published just 210 pages in that first year. The journal content doubled the second year, publishing four issues with over 400 pages. The growth of the journal continued, with a move to six issues per year from 1996, with 500 to 700 pages per year. The final change was a move to eight issues per year in 2006, with over 800 pages published per year. 2020 was a landmark year in which the journal first published just over 1,000 pages, with the subsequent years 2021 and 2022 publishing just shy of 1,000 pages (994 pages in each year). STH published a more standard 866 pages in 2023. The year 2024 saw the page count jump to well above 1,000 pages, primarily because we published additional historical content, as related to our celebration of the anniversary of 50 years of STH publishing. Given that STH is now publishing primarily as an online journal, the publisher has also removed the theoretical cap of 1,000 pages per year, and future years will likely see an increase in annual page count per year.

Fig. 7 Number of items published in Seminars in Thrombosis and Hemostasis per year according to PubMed, from year 1974 to 2024. These counts include online early (eFirst) articles.

[Fig. 7] shows the number of articles published by year as listed in the PubMed database. Although STH publishes a similar number of articles per year in the final print editions, these articles are increasingly being published earlier online (as eFirst), and now also as a pre-eFirst “Accepted” format for some manuscripts. This means an increasing number of papers appearing on PubMed much earlier than the final print publication date.

This leads me to some final comments about “anniversaries.” The year 2023 marked the 50th year of STH publishing, and the year 2024 marked the “official” 50th “birthday” for STH. Similar to what we did to mark the 40th year anniversary in 2014, where we published two issues of STH to celebrate,[61] [62] we actually managed to compile four issues to celebrate the 50th anniversary landmark. The first of these issues appeared as the last issue (November) of 2022,[55] the second early in 2023,[56] the third as the first issue of 2024,[63] and the fourth and final in mid 2024,[64] in time to celebrate our 50th birthday at the International Society on Thrombosis and Hemostasis (ISTH) 2024 meeting in Bangkok, Thailand.[4] Two of these celebratory issues managed to achieve both high citations (see above) and also high popularity.[3] [4] I look forward to seeing the other two celebratory issues in future listings. 2025 marks my 16-year association with the journal as Editor in Chief, an event reflecting a kind of halfway point in comparison to Eberhard Mammen, who steered STH as Editor in Chief for some 34 years.[65] I look forward to at least another year of my association with this journal!

 

MissingLinkText

 

MissingLinkText

Conflict of Interest

None declared.

• References

• 1 Favaloro EJ. New STH (2020) impact factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2021; 47 (07) 745-753
• 2 Favaloro EJ. New Seminars in Thrombosis and Hemostasis (STH) 2021 impact factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2022; 48 (06) 634-642
• 3 Favaloro EJ. New Seminars in Thrombosis and Hemostasis 2022 impact factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2023; 49 (07) 661-669
• 4 Favaloro EJ. New STH 2023 impact factor, most highly cited papers, and other journal metrics. Semin Thromb Hemost 2024; 50 (08) 1058-1066
• 5 WHO. COVID-19 dashboard. Accessed June 21, 2025 at: https://data.who.int/dashboards/covid19/cases
• 6 COVID-19 vaccination, World data. Accessed June 21, 2025 at: https://data.who.int/dashboards/covid19/vaccines?n=o
• 7 National Library of Medicine/National Center for Biotechnology Information/PubMed.com. Accessed June 21, 2025 at: https://pubmed.ncbi.nlm.nih.gov/?term=COVID-19+or+COVID19+or+SARS-CoV-2&sort=date&size=200
• 8 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part I. Semin Thromb Hemost 2020; 46 (07) 757-762
• 9 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part II. Semin Thromb Hemost 2021; 47 (04) 333-337
• 10 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part III. Semin Thromb Hemost 2022; 48 (01) 3-7
• 11 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
• 12 Favaloro EJ. 2021 Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2021; 47 (05) 467-476
• 13 Favaloro EJ. 2022 Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2022; 48 (05) 502-513
• 14 Favaloro EJ. 2023 Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2023; 49 (05) 417-426
• 15 Favaloro EJ. Eberhard F. Mammen Award announcements: part I-most popular articles. Semin Thromb Hemost 2024; 2024 (Mar): 8 . Epub ahead of print
• 16 Favaloro EJ. The Journal Impact Factor: don't expect its demise any time soon. Clin Chem Lab Med 2009; 47 (11) 1319-1324
• 17 Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008; 34 (01) 7-25
• 18 Morrow GB, Mutch NJ. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Semin Thromb Hemost 2023; 49 (03) 305-313
• 19 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
• 20 Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 55-61
• 21 Hartmann J, Dias JD, Pivalizza EG, Garcia-Tsao G. Thromboelastography-guided therapy enhances patient blood management in cirrhotic patients: a meta-analysis based on randomized controlled trials. Semin Thromb Hemost 2023; 49 (02) 162-172
• 22 Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022; 48 (08) 978-987
• 23 Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022; 48 (06) 643-660
• 24 Okholm SH, Krog J, Hvas AM. Tranexamic acid and its potential anti-inflammatory effect: a systematic review. Semin Thromb Hemost 2022; 48 (05) 568-595
• 25 Bowyer AE, Gosselin RC. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin Thromb Hemost 2023; 49 (06) 609-620
• 26 Thachil J, Favaloro EJ, Lippi G. D-dimers—“normal” levels versus elevated levels due to a range of conditions, including “D-dimeritis,” inflammation, thromboembolism, disseminated intravascular coagulation, and COVID-19. Semin Thromb Hemost 2022; 48 (06) 672-679
• 27 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023; 49 (06) 621-633
• 28 Turner S, Naidoo CA, Usher TJ. et al. Increased levels of inflammatory and endothelial biomarkers in blood of long COVID patients point to thrombotic endothelialitis. Semin Thromb Hemost 2024; 50 (02) 288-294
• 29 Grobbelaar LM, Kruger A, Venter C. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022; 48 (07) 858-868
• 30 Richard M, Celeny D, Neerman-Arbez M. Mutations accounting for congenital fibrinogen disorders: an update. Semin Thromb Hemost 2022; 48 (08) 889-903
• 31 Bartlett R, Arachichilage DJ, Chitlur M. et al. The history of extracorporeal membrane oxygenation and the development of extracorporeal membrane oxygenation anticoagulation. Semin Thromb Hemost 2024; 50 (01) 81-90
• 32 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
• 33 Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost 2023; 49 (08) 848-860
• 34 Hu M, Li X, Yang Y. Causal associations between cardiovascular risk factors and venous thromboembolism. Semin Thromb Hemost 2023; 49 (07) 679-687
• 35 Adcock DM, Moore GW, Montalvão SL, Kershaw G, Gosselin RC. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Semin Thromb Hemost 2023; 49 (06) 571-579
• 36 Devreese KMJ. Solid phase assays for antiphospholipid antibodies. Semin Thromb Hemost 2022; 48 (06) 661-671
• 37 Larsen JB, Hvas AM, Hojbjerg JA. Platelet function testing: update and future directions. Semin Thromb Hemost 2023; 49 (06) 600-608
• 38 Casini A, Moerloose P, Neerman-Arbez M. One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48 (08) 880-888
• 39 Favaloro EJ, Dean E, Arunachalam S. Variable performance of lupus anticoagulant testing: the Australasian/Asia-Pacific experience. Semin Thromb Hemost 2024; 50 (08) 1103-1113
• 40 Mabrouk M, Guessous F, Naya A, Merhi Y, Zaid Y. The pathophysiological role of platelet-derived extracellular vesicles. Semin Thromb Hemost 2023; 49 (03) 279-283
• 41 Ortega-Paz L, Talasaz AH, Sadeghipour P. et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (08) 816-832
• 42 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
• 43 Bikdeli B, Muriel A, Wang Y. et al; RIETE Investigators. Sex-related differences in patient characteristics, risk factors, and symptomatology in older adults with pulmonary embolism: findings from the SERIOUS-PE Study. Semin Thromb Hemost 2023; 49 (07) 725-735
• 44 Boccatonda A, Balletta M, Vicari S, Hoxha A, Simioni P, Campello E. The journey through the pathogenesis and treatment of venous thromboembolism in inflammatory bowel diseases: a narrative review. Semin Thromb Hemost 2023; 49 (07) 744-755
• 45 Gyldenholm T, Hvas AM, Christensen TD, Larsen JB. Thrombin generation markers as predictors of cancer-associated venous thromboembolism: a systematic review. Semin Thromb Hemost 2024; 50 (03) 384-401
• 46 Shavit-Stein E, Berkowitz S, Gofrit SG, Altman K, Weinberg N, Maggio N. Neurocoagulation from a mechanistic point of view in the central nervous system. Semin Thromb Hemost 2022; 48 (03) 277-287
• 47 Lira AL, Kohs TCL, Moellmer SA, Shatzel JJ, McCarty OJT, Puy C. Substrates, cofactors, and cellular targets of coagulation factor XIa. Semin Thromb Hemost 2024; 50 (07) 962-969
• 48 Radin M, Cecchi I, Arbrile M. et al. Pediatric presentation of antiphospholipid syndrome: a review of recent literature with estimation of local prevalence. Semin Thromb Hemost 2024; 50 (02) 182-187
• 49 George JN. Thrombotic thrombocytopenic purpura: from 1972 to 2022 and beyond. Semin Thromb Hemost 2022; 48 (08) 926-936
• 50 Kearney KJ, Ariëns RAS, Macrae FL. The role of fibrin(ogen) in wound healing and infection control. Semin Thromb Hemost 2022; 48 (02) 174-187
• 51 Schellong S, Ageno W, Casella IB. et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE Study. Semin Thromb Hemost 2022; 48 (04) 446-458
• 52 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
• 53 Bor MV, Feddersen S, Pedersen IS, Sidelmann JJ, Kristensen SR. Dysfibrinogenemia-potential impact of genotype on thrombosis or bleeding. Semin Thromb Hemost 2022; 48 (02) 161-173
• 54 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
• 55 Favaloro EJ. Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part I. Semin Thromb Hemost 2022; 48 (08) 871-874
• 56 Favaloro EJ. Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part II. Semin Thromb Hemost 2023; 49 (03) 212-216
• 57 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing-part II. Semin Thromb Hemost 2023; 49 (06) 569-570
• 58 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing-part I. Semin Thromb Hemost 2022; 48 (06) 631-633
• 59 Schulman S. Recent advances in thrombosis and hemostasis-part IX. Semin Thromb Hemost 2023; 49 (07) 670-672
• 60 Favaloro EJA. 2018 update on the editorial and publication policy of Seminars in Thrombosis and Hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
• 61 Favaloro EJ. A short history of Thrombosis and Hemostasis: part I (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (05) 521-525
• 62 Favaloro EJ. A short history of Thrombosis and Hemostasis: part II (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (08) 826-830
• 63 Favaloro EJ. Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part III. Semin Thromb Hemost 2024; 50 (01) 4-7
• 64 Favaloro EJ. Celebrating 50 years of Seminars in Thrombosis and Hemostasis-part IV. Semin Thromb Hemost 2024; 50 (05) 677-681
• 65 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (08) 703-707

Publikationsverlauf

Artikel online veröffentlicht:
09. Juli 2025